Prohost's Beliefs About the Status of the Market
That the market is still volatile and Bear. Investors in the biotech sector who intend to bet on clinical stage firms must restrict their choices to companies that already have proof of concept regarding safety and efficacy in some midterm and pre-term clinical trial results.

Caution is still important for clinical-stage firms’ stocks that have encouraging clinical trial results, as the biotech stocks’ values are currently dictated by the market performance rather than by promising or failing clinical trial results.

Trustable are only the final clinical trials that demonstrate . . .